Results 41 to 50 of about 762,366 (142)

Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort

Diagnostics, 2023
The Homologous Recombination Deficiency (HRD) Score, determined by evaluating genomic instability through the assessment of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), serves as a crucial ...
Viorica-Elena Rădoi, Mihaela Țurcan, Ovidiu Virgil Maioru, Andra Dan, Laurentiu Camil Bohîlțea, Elena Adriana Dumitrescu, Adelina Silvana Gheorghe, Dana Lucia Stănculeanu, Georgia Thodi, Yannis L. Loukas, Ileana-Delia Săbău   +10 more
doaj   +1 more source

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

Diagnostics, 2019
Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway.
Stergios Boussios, Afroditi Karathanasi, Deirdre Cooke, Cherie Neille, Agne Sadauskaite, Michele Moschetta, Nikolaos Zakynthinakis-Kyriakou, Nicholas Pavlidis   +7 more
doaj   +1 more source

Indications and timing for genetic testing in ovarian cancer

Journal of Medical Science
Modern management of ovarian cancer (OC) relies on molecular diagnostics, with genetic testing playing a central role in therapeutic decisions. High-grade serous ovarian cancer (HGSOC) is frequently associated with mutations in the BRCA1 and BRCA2 genes,
Cezary Miedziarek, Maksymilian Markwitz, Michał Potograbski, Mikołaj Piotr Zaborowski   +3 more
doaj   +1 more source

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Nature Communications, 2023
Homologous recombination deficiency is linked with platinum-based chemotherapy response in triple-negative breast cancer (TNBC) but methods to clinically identify these patients are lacking.
Petra ter Brugge, Sarah C. Moser, Ivan Bièche, Petra Kristel, Sabrina Ibadioune, Alexandre Eeckhoutte, Roebi de Bruijn, Eline van der Burg, Catrin Lutz, Stefano Annunziato, Julian de Ruiter, Julien Masliah Planchon, Sophie Vacher, Laura Courtois, Rania El-Botty, Ahmed Dahmani, Elodie Montaudon, Ludivine Morisset, Laura Sourd, Léa Huguet, Heloise Derrien, Fariba Nemati, Sophie Chateau-Joubert, Thibaut Larcher, Anne Salomon, Didier Decaudin, Fabien Reyal, Florence Coussy, Tatiana Popova, Jelle Wesseling, Marc-Henri Stern, Jos Jonkers, Elisabetta Marangoni   +32 more
doaj   +1 more source

Homologous Recombination Deficiency in Breast Cancer: A Clinical Review

, 2017
BRCA1 and BRCA2 germline mutation–associated breast cancers are known to be deficient in the process of homologous recombination and often respond favorably to drugs targeting this important DNA repair pathway.
Anna V. Tinker, Eric Yang Zhao, Kasmintan A. Schrader, Samuel Aparicio, Karen A. Gelmon, Wendie D. den Brok, Sophie Sun   +6 more
core   +1 more source

Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer

Gynecologic Oncology Reports
Objective: We sought to establish a process for increasing somatic tumor testing for patients with germline BRCA negative advanced stage epithelial ovarian cancer (EOC) and to gain insight into patients’ comprehension of their genetic testing. Methods: A
Casey L. Lawler, Sara M. Klennert, Kristin C. Cole, Karen S. Schaepe, Laura J. Ongie, Megan E. Grudem, Carolyn M. Klampe, Myra J. Wick, Vonda M. Wall, Sanjna Rajput, Clarissa L. Polen-De, Amanika Kumar   +11 more
doaj   +1 more source

Analysis of homologous recombination deficiency in prostate cancer

Сибирский онкологический журнал
Background. Mutations in homologous recombination repair (HRR) genes (BRCA2, ATM, CHEK2, NBN, etc.) are found in 20–25 % of patients with metastatic prostate cancer (PC) and are an indication for prescription of PARP inhibitors.
A. G. Iyevleva, S. N. Aleksakhina, A. P. Sokolenko, E. A. Otradnova, A. S. Nikitina, K. A. Kashko, M. V. Syomina, N. S. Morozova, A. D. Shestakova, E. Sh. Kuligina, E. N. Imyanitov   +10 more
doaj   +1 more source

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Nature Communications, 2020
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate with
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley, Divya Kriplani, Heidi Gevensleben, Helen Ruth Davies, Andrea Degasperi, Rebecca Roylance, Stephen Chan, Andrew Tutt, Anthony Skene, Abigail Evans, Judith M. Bliss, Serena Nik-Zainal, Nicholas C. Turner   +21 more
doaj   +1 more source

Homologous Recombination and the Formation of Complex Genomic Rearrangements [PDF]

, 2019
International audienceThe maintenance of genome integrity involves multiple independent DNA damage avoidance and repair mechanisms. However, the origin and pathways of the focal chromosomal reshuffling phenomena collectively referred to as chromothripsis
Heyer, Wolf-Dietrich, Piazza, Aurèle
core   +1 more source

Homologous recombination deficiency among patients with germline or somatic non-BRCA1/2 homologous recombination repair gene variations

npj Precision Oncology
This study examined the relationship between homologous recombination deficiency (HRD) and variations in non-BRCA1/2 homologous recombination repair (HRR) genes.
Yue Li, Xinhua Yang, Haoyang Cai, Fang Wang   +3 more
doaj   +1 more source